- Home
- GBX vs CVAC Comparison
GBX vs CVAC Comparison
Compare GBX & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBX
- CVAC
- Stock Information
- Founded
- GBX 1974
- CVAC 2000
- Country
- GBX United States
- CVAC Germany
- Employees
- GBX N/A
- CVAC N/A
- Industry
- GBX Railroads
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- GBX Industrials
- CVAC Health Care
- Exchange
- GBX Nasdaq
- CVAC Nasdaq
- Market Cap
- GBX 1.5B
- CVAC 1.2B
- IPO Year
- GBX N/A
- CVAC 2020
- Fundamental
- Price
- GBX $46.02
- CVAC $5.38
- Analyst Decision
- GBX Hold
- CVAC Hold
- Analyst Count
- GBX 2
- CVAC 3
- Target Price
- GBX $59.50
- CVAC $6.83
- AVG Volume (30 Days)
- GBX 256.0K
- CVAC 411.6K
- Earning Date
- GBX 10-28-2025
- CVAC 11-11-2025
- Dividend Yield
- GBX 2.79%
- CVAC N/A
- EPS Growth
- GBX 88.14
- CVAC N/A
- EPS
- GBX 7.10
- CVAC 1.01
- Revenue
- GBX $3,533,700,000.00
- CVAC $599,540,810.00
- Revenue This Year
- GBX N/A
- CVAC N/A
- Revenue Next Year
- GBX N/A
- CVAC $23.83
- P/E Ratio
- GBX $6.47
- CVAC $5.34
- Revenue Growth
- GBX 0.70
- CVAC 675.15
- 52 Week Low
- GBX $37.77
- CVAC $2.37
- 52 Week High
- GBX $71.06
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- GBX 51.44
- CVAC 47.31
- Support Level
- GBX $45.20
- CVAC $5.34
- Resistance Level
- GBX $46.43
- CVAC $5.41
- Average True Range (ATR)
- GBX 1.04
- CVAC 0.04
- MACD
- GBX 0.09
- CVAC -0.00
- Stochastic Oscillator
- GBX 76.23
- CVAC 31.58
About GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of its revenue from the United States.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.